Click here to access the guidelines/NICE algorithm

| N&WICS - TA691 - Avelumab - Untreated metastatic Merkel cell carcinoma | | |
|---|---|---|
| Before providing patient identifiable data on this form, please confirm that the patient (or in the case of a minor or vulnerable adult with the parent/legal guardian/carer) has given appropriate explicit consent for sensitive personal information on this form to be passed to the CCG and/or CSU for processing this funding request and validating subsequent invoices. Consent given: ☐<br><br>If there is more than one NICE-approved treatment available, a discussion between the responsible clinician and the patient has taken place about the advantages and disadvantages of the treatments available. This has taken into consideration therapeutic need and whether or not the patient is likely to adhere to treatment. The most appropriate, least expensive, will be chosen (taking into account administration costs, dosage and price per dose) unless an order of preference is stated in the TAs. ☐ | | |
| **Patient NHS No:** | **Trust:** | **Practice Name:** |
| **Patient Hospital No:** | **Consultant Making Request:** | **Practice Postcode:** |
| **Patient's Initials and DoB:** | | **Practice Code:** |
| **Notification Email Address:** (@NHS.net account ONLY) | | **Contact name & number:** |
| **Start date of requested treatment:** | **Provider:** ☐ Private ☐ NHS<br>**Supplier:** ☐ Homecare ☐ Hospital | **Sub-Type:** N/A<br>**(if applicable)** |
| By completing this form, you confirm that you intend to use the requested medicinal product described below as agreed in the local commissioning statement. Any requests which fall outside of this use will require an individual funding request (IFR).<br><br>For support regarding IFRs, please contact: norfolkicd@nhs.net<br><br>For support regarding the criteria listed below, please contact: norfolknontariff@nhs.net<br><br>The following form references TA517. | | |

| Please indicate whether patient meets the following NICE criteria: | Please tick |
|---|---|
| 1. Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease. It is recommended only if the company provides avelumab according to the commercial arrangement.<br><br>• Why the committee made this recommendation<br><br>• This appraisal reviews the additional evidence collected in the Cancer Drugs Fund managed access agreement for avelumab for metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease (NICE technology appraisal guidance 517). The new evidence includes data from clinical trials and from people having treatment in the NHS while this treatment was available in the Cancer Drugs Fund in England.<br><br>• Avelumab is routinely available in the NHS for treating metastatic Merkel cell carcinoma after chemotherapy. Evidence collected while avelumab was in the Cancer Drugs Fund shows that it is an effective treatment for untreated disease. It shows that, compared with chemotherapy, avelumab improves how long people have before their disease progresses and how long they live.<br><br>• Avelumab is considered to be a life-extending treatment at the end of life. Cost-effectiveness estimates for avelumab are within what NICE consider an acceptable use of NHS resources. Therefore, it is recommended. | ☐ Yes ☐ No |
| 2. As per NICE guidance, treatment should normally be started with the least expensive drug (considering the dose required, price per dose and any additional administration costs).<br><br>Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.<br><br>Where an alternative lower cost treatment is available and has not been tried by the patient, please confirm | ☐ Yes ☐ No |

| | |
|---|---|
| that the clinical rationale for prescribing has been included in the patients' medical record for the purpose of auditing. | |
| 3. The product is being used as described by local commissioning position. | ☐ Yes ☐ No |

| | |
|---|---|
| **I confirm that the patient meets the criteria for treatment**<br><br>Name of person completing:<br><br>Designation of person completing: | <br><br>Contact Details:<br><br>Date: |
| Trust Authorising Pharmacist<br><br>Name:<br>Date: | |